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Background to the reviews 
 
There are 13.7 million new stroke cases globally per year, with a total of 80.1 million stroke survivors 
(GBD 2019). It is the second most common cause of death in the world and is attributed to 6.17 
million deaths per year (GBD 2018). Around one in four people can expect to have a stroke within 
their lifetime (Feigin et al. 2017). The consequences of stroke can include reduced mobility (Michael 
et al. 2005), limb weakness, spasticity, pain, psychosocial issues, language difficulties (Norrving and 
Kissela 2013) and reduced quality of life (Bays 2001).   
After a stroke or a transient ischaemic attack [TIA] people have a substantial long-term risk of 
recurrent stroke (van Wijk et al. 2005; Dhamoon et al. 2006; Feng et al. 2010; Edwards et al. 2017). 
Secondary prevention medication is an important (Kikuchi et al. 2012; Hankey 2014) and effective 
strategy to reduce the risk of stroke recurrence (Toyoda 2009; Hill and Hare 2019). However, 
medication adherence and medication persistence rates are low after stroke (Zhang et al. 2019).  It is 
KEY POINTS 
• Patients who present with an existing 
disability, reduced cognitive function, take 
multiple medications, have a poor quality 
of life, and have had a previous stroke are 
associated with reduced medication 
adherence.  
• There is evidence that trust and belief in 
the medication are important modifiable 
factors which are linked to positive 
medication adherence. 
• There is some evidence that education may 




important to understand stroke survivors’ and carers’ experiences of medication-taking after stroke, 
barriers and facilitators of medication adherence, and the effectiveness of interventions to improve 
them in order to provide effective support. 
This commentary aims to critically appraise the methods used within three systematic reviews 
exploring medication adherence after stroke (AlShaikh et al 2016, Bridgwood et al 2018, Gibson et al 
2020) and to synthesise the findings in the context of clinical practice.  
Methods and Quality of the reviews 
 
Selection of reviews was based on relevance to the broader issues surrounding medication 
adherence in a stoke population, rather than focussing on one moderating factor, e.g. the 
association with cognitive impairment.  Additionally, they were the most recent reviews in this area. 
The three reviews focused on specific populations of stroke survivors (Al AlShaikh et al. 2016; 
Bridgwood et al. 2018; Gibson et al. 2020) and informal primary and secondary care (Gibson et al. 
2020). They used qualitative and quantitative review techniques to explore three key aspects of 
medication adherence: 
1. Quantitative - Meta-analysis: What are the important moderating factors in relation to 
medication non-adherence after stroke? (Al AlShaikh et al. 2016).  
2. Qualitative - Meta-ethnography: What are the views and lived experiences of community-
dwelling stroke survivors, caregivers and health care professionals related to medication 
taking? (Gibson et al. 2020).   
3. Quantitative - Meta-analysis: What interventions are effective in improving medication 
taking? (Bridgwood et al. 2018). 
Outcomes for the reviews explored views, experiences, beliefs, strategies, solutions, factors which 
influence adherence, and adherence itself. Using the PICO tool (Schardt et al. 2007) as an organising 
framework, components of clinical evidence were compared for each review (see Table 1).  
Table 1: PICO of AlShaikh et al 2016, Gibson et al 2019 and Bridgwood et al 2018 
PICO (AlShaikh et al 2016) 
 
(Gibson et al 2019) 
 
(Bridgwood et al 2018) 
 
Population Adults who have 
suffered a stroke 
Community-dwelling 
stroke or TIA survivors, 
informal carers, primary or 
secondary care HCPs who 
prescribe medication-
taking after TIA or stroke 
Adults with a confirmed 
diagnosis of ischaemic stroke, 





prevention of recurrent 
cardiovascular events 
Being prescribed or being 
involved in the 
prescription of medication 
Interventions which aimed to 
improve modifiable risk factor 
control through increased 
adherence  
Control Not applicable Not applicable Yes: Usual care 
Outcomes  
 
Factor(s) that influenced 
medication adherence. 
Lived experiences, views 
and 
beliefs, strategies and 
solutions.  
Patient outcomes such as 
body mass index, blood 






No study type specified. Qualitative studies and 
mixed methods 
Randomised controlled trials, 
parallel group trials, cluster-
randomised 
trials and cross-over trials 
 
Using a modified Joanna Briggs Institute Critical Appraisal tool for systematic reviews (Joanna Briggs 
Institute 2017), it was judged that the systematic reviews by Gibson et al 2020 and Bridgwood et al 
2018 used appropriate methods for all 11 criteria (See Table 2 for full list of criteria and 
corresponding methods) and provided an accurate summary of the results of the included studies. 
The other systematic review (AlShaikh et al 2016) used appropriate methods for only 9 of 11 criteria. 
The screening methods were not appropriate, as although the first stage of dual independent title 
screening was appropriate (Mateen 2013; Rathbone et al. 2017), the second stage of single reviewer 
full paper screening was not (Buscemi et al. 2006; Waffenschmidt et al. 2019). The review also 
lacked a description of the data extraction methods used. Both of these issues can lead to errors and 
exclusion of eligible studies, but overall AlShaikh et al (2016) probably provides an accurate 
summary of the results of the available studies.  
 
Table 2: Quality assessment and methods of AlShaikh et al 2016, Gibson et al 2019 and Bridgwood 
et al 2018 (Quality assessment of the systematic reviews was carried out by JH and JH).  
Criteria (AlShaikh et al 2016) 
 
(Gibson et al 2019) 
 
(Bridgwood et al 2018) 
 




Yes: The aim of this 
review was to identify 
factors associated with 
non-adherence after 
stroke. 
Yes: The aim of this 
review was to 
undertake a meta-
synthesis of qualitative 
studies of medication-
taking after stroke. 
With a focus on lived 
experiences, views and 
beliefs, strategies and 
solutions. 
Yes: To assess the 





on modifiable risk 
factor control.  





Yes: See Table 1 for full 
PICO criteria. 
Yes: See Table 1 for full 
PICO criteria. 
Yes: See Table 1 for full 
PICO criteria. 
3. Was the search 
strategy 
appropriate?  
Yes: A robust multi-
database search was 
undertaken. 
Yes: A robust multi-
database search was 
undertaken and 
snowball sampling. 
Yes: A robust multi-
database search was 
undertaken and 
snowball sampling. 
4. Were the 
sources and 
resources used to 
screen studies 
adequate?  
No: The first stage of 
screening used two 
reviewers 
independently 
reviewing titles only. 
Full paper screening 
was done by single 
reviewer.  
Yes: Title and full paper 
screening was carried 
out by two 
independent reviewers 
Yes: Title and full paper 
screening was carried 
out by two 
independent reviewers 








Scales (Wells 2019) and 
Cochrane Library tool 
for assessing risk of bias 
was used (Higgins et al. 
2011). 
and Downe’s criteria 
was used to assess the 
quality of the included 
studies. 
were assessed using 
the Cochrane risk of 








Yes: Two independent 
reviewers critically 
appraised all included 
studies 
Yes: Two independent 
reviewers critically 
appraised all included 
studies 
Yes: Three independent 
reviewers critically 







No: No description of 
whether data extraction 
was carried out 
independently and 
duplicated.  
Yes: Data extraction 
was carried out by two 
independent reviewers 
using a bespoke pre-
piloted data extraction 
form. 
Yes: Data extraction 
was carried out by two 
independent reviewers 
using a pre-specified 
data extraction form 
8.Were the 
methods used to 
combine studies 
appropriate? 
Yes: A random effects 
model was used. 
Yes: The use of the 
meta-synthesis 
technique by Noblit 
and Hare was used 
(Noblit 1988). 
Yes: A random effects 
model was used for 
each prespecified 
intervention category; 
subgroup analysis was 
carried out for patient 
age, condition type, 
stroke severity and 






N/A: Less than 10 
studies (Higgins et al. 
2011). 
N/A Yes: Only visual 




s for policy 
and/or practice 
supported by the 
reported data?  
Yes: Full findings and 
implications to practice 
will be discussed below. 
Yes: Full findings and 
implications to practice 
will be discussed 
below. 
Yes: Full findings and 
implications to practice 




for new research 
appropriate? 
Yes: Recommendation 
that further research is 
required around which 
interventions are 
effective in improving 
treatment adherence.  
Yes: Particular areas of 
lack of research were 
identified in studies in 
low to moderate 
income countries, 
acute post stroke and 






made based on the 














Quality of studies included in the reviews 
 
The systematic review by AlShaikh et al (2016) identified that the majority of studies had a high risk 
of bias: often, outcome assessors were non-blinded and most studies used only self-reporting of 
adherence. The qualitative systematic review by Gibson et al (2019) identified that the majority of 
studies included were of medium quality. Quality issues included lack of an appropriate theoretical 
framework, data saturation, participant validation, and reporting of important patient data. There 
were also some ethical concerns.  The review by Bridgwood et al (2018) classified the evidence for 
the outcome of adherence to be of low-quality using GRADE (Kavanagh, 2009), because the studies 
included were heterogeneous, had high risk of bias and findings were inconsistent across the 
studies.  The authors concluded that the true effect might be markedly different from the estimated 
effect (Bridgwood et al 2018) See Table 3 for summarisation of quality of included studies. 
 
Table 3: Quality of  studies included in the reviews. 
 AlShaikh et al (2016) 
 
Gibson et al (2020) 
 
Bridgwood et al (2018) 
 
Critical appraisal 
tool used for 
summary statement 
of quality 
Scales (Wells 2019) 
and Cochrane Library 
tool (Higgins et al. 
2011) 
Walsh and Downe’s 




Quality score Out of the 29 
included studies 27 
were deemed to be 
of high risk and 2 
were low. 
Of the 12 included 
studies 9 were 
deemed to be of 
moderate quality and 
3 were deemed to be 
of weak quality 
The outcome of 
medication adherence 
was downgraded due to 
heterogeneity, high risk 
of bias and 
inconsistency 
Descriptive term:  High risk of bias 
(study level 










Important factors - Medication non-adherence 
 
AlShaikh (2016) identified predictive factors of non-adherence to secondary preventive medication 
after stroke/TIA.  The review included 16 studies and 69,137 patients.  All included studies provided 
a measure of medication non-adherence, ranging from 11.3% to 45.2%.  Meta-analysis showed that 
overall, nearly a third (30.9%) of participants did not adhere to preventative medication. 
The authors reported their data according to the World Health Organization (WHO) classification of 
predictive factors of non-adherence: patient-related, social and economic, therapy-related, health 
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system or health care team, and condition (stroke)-related factors (World Health Organisation 2003).  
The most commonly reported factors which related to increased medication adherence were 
patients who have a positive belief in the medication, the presence of a carer or living in a care 
home, understanding of the medication rationale and having previous treatment by the same 
medication class respectively. The most commonly reported factors which related to reduced 
medication adherence were patients who have a disability 
reduced cognitive function, number and frequency of prescribed drugs, more severe stroke and 
concerns about their medication. See Table 4 most frequently reported medication adherence 
factors. 
 




Patient related factors Number of studies 
which reported the 






Patients who reported 
with concerns about 
their medication 
4 Negatively 
Patients had a positive 




Presence of a carer or 
living at home rather 
than in institutional 
care 
4 Positively 









Poor quality of life  3 Negatively 
Low mood 2 Negatively 
Smoking 2 Negatively 








treatment by the same 
medication class 
3 Positively 
Cost of medication 3 Negatively 
Number and frequency of 
prescribed drugs 
4 Negatively 
Health system or 
health care team 
factors 
Treated in stroke unit 2 Positively 
Medical insurance 2 Positively 
Accessible health care 
facility 
2 Positively 
Stroke-related factors More severe stroke 4 Negatively 
Previous stroke incidence 3 Negatively 
Symptoms of post-






Four factors were eligible for meta-analysis: absent history of atrial fibrillation, disability, 
polypharmacy and age of the patient, but no significant associations with medication adherence 
were found. 
The review authors noted that much of the available literature was based on patient or drug factors,  
but institution or healthcare factors should not be forgotten.  They suggest that clinicians could 
reduce the burden of treatment on patients by communicating the barriers of adherence and 
identifying factors that could be reversed such as mis-beliefs or complex regimens. The authors 
imply that it is important to identify interventions that can detect difficulties for medication 
administration and effectively support patients to adhere to secondary preventative medication. 
 
Views and lived experiences related to medication taking 
 
Gibson et al. (2020) explore the views and lived experiences of taking medicine after stroke from the 
perspective of community-dwelling stroke survivors, informal carers, and healthcare professionals. 
The review identified 12 studies including 412 participants, of which two thirds were stroke survivors 
between 1 month to 20 years post-stroke.   
Two overall themes were developed: ‘doing medicines work’ (all the work that goes into taking 
medications) and ‘trust’ (having trust in the medicines’ efficacy and beliefs about healthcare).  The 
theme of ‘doing medicines work’ included several types of work: information work, healthcare work, 
carer work, emotional work, and practical work, which were classified as sub-themes.   
‘Information work’ focussed on the work patients do to understand and process the information 
about their medication such as why they are taking it and how to take it.  Healthcare professionals 
are often the ones to provide this information and stroke survivors reported both positive and 
negative interactions in this respect.  With healthcare professionals taking the time to explain the 
medications and answering questions to be a positive example of information work. However, it was 
felt that this positive experience was inconsistently delivered and there was a need for medication 
information to be provided long-term.  
The sub-theme of ‘healthcare work’ provided further insight into how patients engage with 
healthcare services to obtain their medication, including monitoring and medicines reviews. Positive 
aspects included healthcare professionals being responsive to patients’ medication concerns and 
difficulties. Negative aspects included patients’ dislike of monitoring/review and the perceived 
negative consequence of additional medication being prescribed.   
‘Carer work’ included support given by family members, friends, or neighbours to obtain, organize or 
supervise medication for the stroke survivor.  It was acknowledged that this could cause conflict in 
the relationship and give rise to difficulties if the carer were not available.   
‘Emotional work’ described the thoughts and feelings of stroke survivors as to why they need to take 
medication, primarily to avoid having another stroke.  This was seen by healthcare professionals as a 
key motivator for medication adherence.  Within this theme it was also noted that some stroke 
survivors had concerns about or disliked taking medication due to, for example, potential side-
effects and stigma.  
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‘Practical work’ included the necessary activity required for a stroke survivor to take their 
medication such as storing and keeping track of doses, often relying on interaction with carers.  
Successful medication adherence required maintenance of a stable routine.  In contrast a complex 
routine or one that required modification acted as a barrier to medication adherence. 
The second main theme in this review was ‘trust’. This relates to stroke survivors’ and carers’ belief 
in the efficacy of the prescribed medication.  This could be hampered by the lack of obvious 
immediate benefit, but if there was a visible end point such as blood pressure reduction, this 
enhanced their trust in the efficacy of the medication.  Furthermore, taking medication was 
mediated by a mutual trust between patients, carers and healthcare professionals.   
The authors conclude that the substantial work required in ‘medicines work’ and the need for ‘trust’ 
in both the medicines and healthcare service ‘are likely to constitute a substantial treatment burden 
regardless of the severity of the stroke’.  In order to address this burden, the authors propose that 
healthcare professionals need to offer a clear information exchange with stroke survivors, reducing 
the amount of work involved for patients in accessing medication support, develop individualised 
strategies to address practical problems, help carers to support and ensure that patient  concerns 
about medication and recurrent stroke are addressed. 
 
What is effective in improving medication taking after stroke? 
The Cochrane review by Bridgwood et al. (2018) synthesised studies of interventions for improving 
modifiable risk factor control in secondary prevention of stroke.  The authors identified 42 random 
controlled trials [RCTs] with 33,840 participants, mostly in primary care or community settings.  
Twenty-six studies evaluated organisational interventions (changing how the healthcare service is 
provided) and 16 evaluated educational or behavioural interventions for participants.  Most 
interventions lasted between three and twelve months with follow up from three months to three 
years.  For most of the interventions, the comparator was standard care (30 RCTs).  The remaining 
studies used active control comparators (4 RCTs) or provided educational but not individualised 
advice (7 RCTs).  One study asked the control group to record stroke consultations/adverse events. 
Organisational interventions consisted of those that formed part of a broader rehabilitation 
programme post-stroke (7 RCTs) and those that targeted secondary prevention (19 RCTs).  Eight of 
these RCTs included a measure of adherence to secondary preventative medications. There was 
moderate quality evidence that organisational interventions resulted in improved outcomes for 
blood pressure target achievement compared to usual care (89 more per 1000 achieving their target, 
95%CI: 21 more to 159 more). The eight RCTs which included a measure of adherence were not 
pooled due to substantial heterogeneity in the methods used. The majority of RCTs [low quality 
evidence] did not find a statistically significant difference for organisational interventions compared 
to control.  The two RCTs which found a statistically significant difference in medication adherence 
included lifestyle counselling and blood pressure monitoring (Hornnes 2010; McAlister 2014). 
Educational/behavioural interventions largely focussed on modifiable risk factors for stroke (11 
RCTs). The remaining interventions delivered education on secondary stroke prevention as part of 
broader stroke education programmes (5 RCTs).  Thirteen of these studies included a measure of 
adherence to secondary preventative medications.  Data could not be pooled due to methodological 
heterogeneity. The majority of RCTs [low quality evidence] did not find a statistically significant 
difference for educational/behavioural interventions compared to control. All three studies which 
demonstrated a statistically significant difference compared to control included education 
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specifically focused on medication adherence (O’Carroll 2011; Peng 2014; Wan 2016). Two of the 
RCTs included specific goal setting around improving medication adherence routines (O’Carroll 2011; 
Wan 2016). 
 
Within the wider review, the authors found no clear evidence that organisational interventions can 
improve modifiable risk factors or reduce incidence of cardiovascular events.  In addition, 
educational interventions alone are unlikely to bring improvements without additional 
organisational change.  They also noted that interventions which were associated with improved 
outcomes for secondary prevention, usually involved multidisciplinary team working.  Medication 





Application to practice  
 
Patients who present with an existing disability, reduced cognitive function, take multiple 
medications, have a poor quality of life, and have had a previous stroke are associated with reduced 
medication adherence. Subsequently these groups should be seen as a priority for screening and 
treatment.  
There is evidence that trust and belief in the medication are important modifiable factors which are 
linked to positive medication adherence. Thus, it is important to ensure that the patient has trust 
and belief in the effectiveness of the medications being prescribed. This concept of trust has also 
been identified as an important moderating factor for the mutual trust between patient, carers, and 
healthcare workers and should be seen as a vital component of effective medication adherence 
interventions. 
It is important that patients are provided with information about why the medication is given. This 
medication information should be clear, easy to access, continuous, responsive, individualised, and 
accessible for both patients and healthcare workers. The information given to the patient about 
their medication should be given in a timely manner and opportunities should be given to the 
patient to voice any concerns/questions they may have. When designing the medication strategy, 
the regularity of the routine should be considered, as lack of consistency may cause worsened 
medication adherence. As part of this educational strategy the use of goal setting and outcome 




Stroke, medication taking, medication adherence, predictive factors, education 
 
CPD reflective questions  
 
• Which out of the factors identified, which were associated with medication adherence, are 
modifiable? 
• If you are designing an educational strategy for medication adherence what key factors should be 
included? 
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